NexImmune is harnessing the power of precision technology to restore natural immunity in the treatment of life-threatening diseases.

We are a clinical-stage biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary Artificial Immune Modulation (AIM) nanotechnology platform, originally developed at Johns Hopkins University. Our AIM™ platform is the core of our innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted T cell response against a disease.

Our novel AIM™ platform utilizes nanoparticles to act as synthetic dendritic cells to identify and activate natural T cells with all of the key underlying attributes that are critical to fighting cancer and other immune-related diseases. Non-engineered T cells have the potential to provide meaningful clinical benefit for patients by mimicking natural immune response that reduces toxicities and enhances safety.

Our first product candidate, NEXI-001, for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) post-allogeneic transplant, is in Ph1/2 clinical trials.


Our innovative approach to immunotherapy is based on our proprietary AIM™ platform that uses nanoparticles to guide the immune system to direct a T cell response to fight disease.

Learn More

Product Pipeline

Using our technology in cancer, we are developing therapies with T cells that target multiple tumor-relevant antigens.

Learn More

Our Team

Our proven executive team is supported by a board of directors comprised of renowned scientific thought leaders and seasoned biopharma executives.

Learn More

Latest News

Read the latest news and events about the next generation of immunotherapy and other press releases about NexImmune.

Learn More

Contact Us